Johnson & Johnson – 2009 Case Notes Prepared by: Dr. Mernoush Banton Case Authors: Sharynn Tomlin, Matt Milhauser, Bernhard Gierke, Thibault Lefebvre, and Mario Martinez
A.
Case Abstract
Johnson & Johnson (www.JNJ.com) is a comprehensive strategic management case that includes the company’s calendar December 31, 2008 financial statements, competitor information and more. The case time setting is the year 2009. Sufficient internal and external data are provided to enable students to evaluate current strategies and recommend a three-year strategic plan for the company. Headquartered in New Brunswick in the U.S. state of New Jersey, Johnson & Johnson is traded on the New York Stock Exchange under ticker symbol JNJ.
B.
Vision Statement (Actual)
“To maximize the global power of diversity and inclusion to drive superior business results and sustainable competitive advantage.”
C.
Mission Statement (Actual)
“We believe our first responsibility is to the doctors, nurses and patients, to mothers and fathers and all others who use our products and services. In meeting their needs, everything we do must be of high quality. (1, 2) We must constantly strive to reduce our costs in order to maintain reasonable prices. Customers’ orders must be serviced promptly and accurately. Our suppliers and distributors must have an opportunity to make a fair profit. (6) We are responsible to our employees, the men and women who work with us throughout the world. Everyone must be considered as an individual. We must respect their dignity and recognize their merit. They must have a sense of security in their jobs. Compensation must be fair and adequate, and working conditions clean, orderly and safe. We must be mindful of ways to help our employees fulfill their family responsibilities. Employees must feel free to make suggestions and complaints. There must be equal opportunity for employment, development and advancement for those qualified. We must provide competent management, and their actions must be just and ethical. (9) We are responsible to the communities in which we live and work and to the world community as well. We must be good citizens – support good works and charities and bear our fair share of taxes. We must encourage civic improvements and better health and education. We must maintain in good order the property we are privileged to use, protecting the environment and natural resources. (3, 7, 8) Copyright © 2011 Pearson Education Limited
Our final responsibility is to our stockholders. Business must make a sound profit. We must experiment with new ideas. Research must be carried on, innovative programs developed and mistakes paid for. New equipment must be purchased, new facilities provided and new products launched. Reserves must be created to provide for adverse times. When we operate according to these principles, the stockholders should realize a fair return. (4, 5)” 1. 2. 3. 4. 5. 6. 7. 8. 9.
Customer Products or services Markets Technology Concern for survival, profitability, growth Philosophy Self-concept Concern for public image Concern for employees
D.
External Audit
CPM – Competitive Profile Matrix
Weight
J&J Weighte Rating d Score
P&G Weighte Rating d Score
Other Weighted Rating Score
0.11
4
0.44
2
0.22
3
0.33
Global Expansion Organizational Structure
0.10
4
0.40
3
0.30
2
0.20
0.04
3
0.12
2
0.08
4
0.16
Employee Morale
0.05
4
0.20
3
0.15
2
0.10
Technology
0.10
4
0.40
3
0.30
2
0.20
Product Safety
0.11
4
0.44
3
0.33
2
0.22
Customer Loyalty
0.10
4
0.40
3
0.30
2
0.20
Market Share
0.06
4
0.24
3
0.18
2
0.12
Advertising
0.08
3
0.24
4
0.32
2
0.16
Product Quality
0.10
4
0.40
3
0.30
2
0.20
Product Image
0.08
4
0.32
3
0.24
2
0.16
Financial Position
0.07
4
0.28
3
0.21
2
0.14
Total
1.00
Critical Success Factors Price competitiveness
3.88
2.93
Copyright © 2011 Pearson Education Limited
2.19
Opportunities 1. Smaller companies are coming up with new and innovative drugs. This creates an opportunity for larger drug companies to acquire or form a joint venture with smaller companies 2. Larger organizations have better purchasing power in buying raw material 3. The baby boomers are aging, therefore they have more need for health and medical services 4. More consumers are becoming health conscious by taking more vitamins and use better brand health related products 5. Due to economic downturn, many individuals may have more stress and depression and as such, may have a need for prescription drugs 6. Despite years of research, companies still spend money for developing new drugs for health issues related to cancer, heart problems, HIV and Alzheimer’s 7. Through the Internet, drug companies have found a more effective and less expensive way in advertising, educating, and promoting their products Threats 1. The cost of R&D has been increasing at an astounding rate, rising currently at a rate of eightfold per year 2. Due to economic downturn, there has been severe changes in the behavior and spending patterns of purchasers of healthcare products and services 3. Generic drug firms have filed Abbreviated New Drug Applications (ANDAs) seeking to market generic forms of most of the key pharmaceutical products, prior to expiration of the applicable patents covering those products 4. By 2012, many major patents, often referred to as Patent Cliffs, will expire, clearing the way for companies involved in the production of generics to begin manufacturing the most effective and high-grossing drugs on the market 5. Introducing a new drug into the market can take 10 to 15 years and require extensive amount of money to get it tested and receive FDA approval 6. Often, drugs could have side effects which create negative publicity and/or force the company to recall the drug or remove it from the shelves External Factor Evaluation (EFE) Matrix Key External Factors
Weight
Rating
Weighted Score
0.1
4
0.4
0.09
3
0.27
0.1
4
0.4
Opportunities 1. Smaller companies are coming up with new and innovative drugs. This creates an opportunity for larger drug companies to acquire or form a joint venture with smaller companies 2. Larger organizations have better purchasing power in buying raw material 3. The baby boomers are aging, therefore they have more need for health and medical services
Copyright © 2011 Pearson Education Limited
4. More consumers are becoming health conscious by taking more vitamins and use better brand health related products 5. Due to economic downturn, many individuals may have more stress and depression and as such, may have a need for prescription drugs 6. Despite years of research, companies still spend money for developing new drugs for health issues related to cancer, heart problems, HIV and Alzheimer’s 7. Through the Internet, drug companies have found a more effective and less expensive way in advertising, educating, and promoting their products Threats
0.1
4
0.4
0.06
3
0.18
0.06
3
0.18
0.07
4
0.28
1. The cost of R&D has been increasing at an astounding rate, rising currently at a rate of eightfold per year 2. Due to economic downturn, there has been severe changes in the behavior and spending patterns of purchasers of healthcare products and services 3. Generic drug firms have filed Abbreviated New Drug Applications (ANDAs) seeking to market generic forms of most of the key pharmaceutical products, prior to expiration of the applicable patents covering those products 4. By 2012, many major patents, often referred to as Patent Cliffs, will expire, clearing the way for companies involved in the production of generics to begin manufacturing the most effective and high-grossing drugs on the market 5. Introducing a new drug into the market can take 10 to 15 years and require extensive amount of money to get it tested and receive FDA approval 6. Often, drugs could have side effects which create negative publicity and/or force the company to recall the drug or remove it from the shelves Total
0.09
2
0.18
0.08
3
0.24
0.07
2
0.14
0.06
2
0.12
0.05
1
0.05
0.07
2
0.14
1.00
Copyright © 2011 Pearson Education Limited
2.98
Positioning Map Innovation (High)
Pfizer
Novartis Procter & Gamble
Merck & Co. Brand Loyalty (Low)
Johnson & Johnson
Brand Loyalty (High)
Innovation (Low)
E.
Internal Audit Strengths 1. J&J offers a wide variety of products and services to hospitals, retailers, and families 2. The company does business in three segments: pharmaceutical, medical devices and consumer products 3. In July 2009, J&J purchased an 18.4 percent stake in Irish biotech company Elan Corp. in order to gain access to the US$3 billion market for Alzheimer’s disease treatments. The effectiveness of the drug could help the company’s sales by US$25 billion 4. In 2009, J&J acquired the small cancer drug-developer Cougar Biotechnology for about US$894 million in cash. Cougar has an excellent drug for late stage prostate cancer 5. At the end of 2008, J&J reported US$7.6 billion in research and developments expenditures, which was a slight decrease from 2007 6. Sales for both consumer health products and medical devices and diagnostics were up from 2007 to 2008 by 10.8 percent and 6.4 percent, respectively 7. The consumer products segment’s operating profit increased 17.4 percent from 2007 to US$2,674 million in 2008
Copyright © 2011 Pearson Education Limited
8. The pharmaceutical segment operating profit increased 16.3 percent from 2007, and operating profit increased to 31.0 percent to a total of US$7,605 million in 2008 9. Operating profit in medical devices segment increased 49.1 percent from 2007 to a total of US$7,223 million in 2008 Weaknesses 1. Sales for pharmaceutical segment was down from 2007 to 2008 by 1.2 percent 2. Patent on many of their popular and high volume drugs is about to expire 3. Increase in total liabilities by approximately US$4.8 billion from 2007 to 2008 4. In recent years, have not introduced any new innovative product unless by acquiring other companies 5. Per 2009 data, the company’s quarterly sales dropped by 5.3 percent from the same period in prior year 6. The selling, general and administrating expenses to sales increased by 0.30 percent from 2007 to 2008 Financial Ratio Analysis (December 2009) Growth Rates %
J&J
Industry
S&P 500
Sales (Qtr vs year ago qtr)
-5.30
3.20
-4.80
Net Income (YTD vs YTD)
-1.70
5.10
-6.00
Net Income (Qtr vs year ago qtr)
1.10
38.80
26.80
Sales (5-Year Annual Avg.)
8.77
8.49
12.99
Net Income (5-Year Annual Avg.)
12.46
15.83
12.69
Dividends (5-Year Annual Avg.)
14.18
14.40
11.83
Price Ratios
J&J
Industry
S&P 500
Current P/E Ratio
14.1
15.3
26.7
P/E Ratio 5-Year High
25.3
18.2
16.6
P/E Ratio 5-Year Low
10.5
5.0
2.6
Price/Sales Ratio
2.94
3.08
2.25
Price/Book Value
3.53
8.10
3.48
Price/Cash Flow Ratio
11.50
12.20
13.70
Profit Margins %
J&J
Industry
S&P 500
Gross Margin
71.1
72.9
38.9
Pre-Tax Margin
27.5
24.0
10.3
Net Profit Margin
21.1
18.7
7.1
5Yr Gross Margin (5-Year Avg.)
71.5
72.1
38.6
5Yr PreTax Margin (5-Year Avg.)
25.4
21.3
16.6
5Yr Net Profit Margin (5-Year Avg.)
19.1
15.9
11.5
Copyright © 2011 Pearson Education Limited
Financial Condition
J&J
Industry
S&P 500
Debt/Equity Ratio
0.23
2.30
1.09
Current Ratio
1.8
1.9
1.5
Quick Ratio
1.6
1.6
1.3
Interest Coverage
57.1
20.6
23.7
Leverage Ratio
1.8
4.7
3.4
Book Value/Share Adapted from www.moneycentral.msn.com
18.27
11.51
21.63
Avg P/E
Price/ Sales
Price/ Book
Net Profit Margin (%)
12/08
14.20
2.60
3.81
20.3
12/07
17.60
3.21
4.42
17.3
12/06
16.70
3.67
4.86
20.7
01/06
19.30
3.57
4.62
19.9
01/05
20.40
4.01
5.92
17.3
12/03
22.00
3.64
5.59
17.2
12/02
26.60
4.47
6.95
18.2
12/01
28.30
5.67
7.43
17.5
12/00
27.60
5.58
7.76
17.0
12/08
14.20
2.60
3.81
20.3
Book Value/ Debt/ Share Equity
Return Equity (%)
12/08
$15.35
0.28
30.5
15.2
38.9
12/07
$15.25
0.22
24.4
13.1
44.9
12/06
$13.59
0.17
28.1
15.7
231.5
01/06
$13.01
0.07
26.0
17.1
242.9
01/05
$10.71
0.09
25.7
15.3
65.9
12/03
$9.05
0.15
26.8
14.9
49.8
12/02
$7.65
0.18
29.1
16.3
58.1
12/01
$7.95
0.11
23.4
14.7
51.6
12/00
$6.77
0.23
24.3
14.5
33.7
15.2
38.9
12/08 $15.35 0.28 30.5 Adapted from www.moneycentral.msn.com Internal Factor Evaluation (IFE) Matrix Key Internal Factors
on Return on Interest Assets (%) Coverage
Weight
Rating
Strengths
Copyright © 2011 Pearson Education Limited
Weighted Score
1. J&J offers a wide variety of products and services to hospitals, retailers, and families
0.08
4
0.32
2. The company does business in three segments: pharmaceutical, medical devices and consumer products 3. In July 2009, J&J purchased an 18.4 percent stake in Irish biotech company Elan Corp. in order to gain access to the US $3 billion market for Alzheimer's disease treatments. The effectiveness of the drug could help the company's sales by US$25 billion 4. In 2009, J&J acquired the small cancer drugdeveloper Cougar Biotechnology for about US$894 million in cash. Cougar has an excellent drug for late stage prostate cancer 5. At the end of 2008, J&J reported US$7.6 billion in research and developments expenditures, which was a slight decrease from 2007 6. Sales for both consumer health products and medical devices and diagnostics were up from 2007 to 2008 by 10.8 percent and 6.4 percent, respectively 7. The consumer products segment's operating profit increased 17.4 percent from 2007 to US$2,674 million in 2008 8. The pharmaceutical segment operating profit increased 16.3 percent from 2007, and operating profit increased to 31.0 percent to a total of US$7,605 million in 2008 9. Operating profit in medical devices segment increased 49.1 percent from 2007 to a total of US$7,223 million in 2008 Weaknesses
0.08
4
0.32
0.07
4
0.28
0.07
4
0.28
0.08
3
0.24
0.06
3
0.18
0.06
3
0.18
0.06
3
0.18
0.06
3
0.18
1. Sales for pharmaceutical segment was down from 2007 to 2008 by 1.2 percent
0.06
1
0.06
2. Patent on many of their popular and high volume drugs is about to expire
0.09
1
0.09
3. Increase in total liabilities by approximately US$4.8 billion from 2007 to 2008
0.05
2
0.1
4. In recent years, have not introduced any new innovative product unless by acquiring other companies 5. Per 2009 data, the company's quarterly sales dropped by 5.3 percent from the same period in prior year 6. The selling, general and administrating expenses to sales increased by 0.30 percent from 2007 to 2008
0.07
1
0.07
0.04
2
0.08
0.07
2
0.14
Copyright © 2011 Pearson Education Limited
Total
F.
1.00
2.7
SWOT Strategies Strengths 1. J&J offers a wide variety of products and services to hospitals, retailers, and families 2. The company does business in three segments: pharmaceutical, medical devices and consumer products 3. In July 2009, J&J purchased an 18.4 percent stake in Irish biotech company Elan Corp. in order to gain access to the US$3 billion market for Alzheimer’s disease treatments. The effectiveness of the drug could help the company’s sales by US$25 billion 4. In 2009, J&J acquired the small cancer drugdeveloper Cougar Biotechnology for about US$894 million in cash. Cougar has an excellent drug for late stage prostate cancer 5. At the end of 2008, J&J reported US$7.6 billion in research and developments expenditures, which was a slight decrease from 2007 6. Sales for both consumer health products and medical devices and diagnostics were up from 2007 to 2008 by 10.8 percent and 6.4 percent,
Weaknesses 1. Sales for pharmaceutical segment was down from 2007 to 2008 by 1.2 percent 2. Patent on many of their popular and high volume drugs is about to expire 3. Increase in total liabilities by approximately US$4.8 billion from 2007 to 2008 4. In recent years, have not introduced any new innovative product unless by acquiring other companies 5. Per 2009 data, the company’s quarterly sales dropped by 5.3 percent from the same period in prior year 6. The selling, general and administrating expenses to sales increased by 0.30 percent from 2007 to 2008
Copyright © 2011 Pearson Education Limited
respectively 7. The consumer products segment’s operating profit increased 17.4 percent from 2007 to US$2,674 million in 2008 8. The pharmaceutical segment operating profit increased 16.3 percent from 2007, and operating profit increased to 31.0 percent to a total of US$7,605 million in 2008 9. Operating profit in medical devices segment increased 49.1 percent from 2007 to a total of US$7,223 million in 2008 Opportunities
S-O Strategies
W-O Strategies
1. Smaller companies are coming up with new and innovative drugs. This creates an opportunity for larger drug companies to acquire or form a joint venture with smaller companies 2. Larger organizations have better purchasing power in buying raw material 3. The baby boomers are aging, therefore they have more need for health and medical services 4. More consumers are becoming health conscious by taking more vitamins and use better brand health related products 5. Due to economic downturn, many individuals may have
Increase R&D on products related to curing Alzheimer’s, Cardiovascular, and Cancer diseases (S2, S3, S4, S8, O3, O6) Acquire additional companies that are innovative and have pending patents on popular health related products (S2, S8, O1, O3, O4, O6)
1. Increase marketing efforts through social networks and the Internet on consumer, OTC and pharmaceutical products, specific to young generation (W1, O4, O7) 2. Develop new health related products such as vitamins and dietary pills / drinks for health conscious consumers (W4, O3, O4)
Copyright © 2011 Pearson Education Limited
more stress and depression and as such, may have a need for prescription drugs 6. Despite years of research, companies still spend money for developing new drugs for health issues related to cancer, heart problems, HIV and Alzheimer’s 7. Through the Internet, drug companies have found a more effective and less expensive way in advertising, educating, and promoting their products Threats
S-T Strategies
W-T Strategies
1. The cost of R&D has been increasing at an astounding rate, rising currently at a rate of eightfold per year 2. Due to economic downturn, there has been severe changes in the behavior and spending patterns of purchasers of healthcare products and services 3. Generic drug firms have filed Abbreviated New Drug Applications (ANDAs) seeking to market generic forms of most of the key pharmaceutical products, prior to expiration of the applicable patents covering those products 4. By 2012, many major patents, often referred to as Patent Cliffs, will expire, clearing the way for companies
1. Form a partnership/ joint venture (minority interest) with generic drug manufacturers on promoting and educating the health benefits of specific products (S1, S2, S8, T1, T3, T4) 2. Outsource some of R&D procedures and processes in order to reduce R&D cost but ensure the intellectual property remains secure and confidential (S2, S7, S8, S9, T1, T5)
1. Increase advertising and promotion by educating the consumers on the benefits of using brand versus generic drugs (W1, W5, T3, T4) 2. Create a social network area for consumers to discuss their concerns and side effect of drugs so the company can have better track records of issues and be able to improve public image before the issues escalates legally (W1, T6)
Copyright © 2011 Pearson Education Limited
involved in the production of generics to begin manufacturing the most effective and high-grossing drugs on the market 5. Introducing a new drug into the market can take 10 to 15 years and require extensive amount of money to get it tested and receive FDA approval 6. Often, drugs could have side effects which create negative publicity and/or force the company to recall the drug or remove it from the shelves
Copyright © 2011 Pearson Education Limited
G.
SPACE Matrix
FS Conservative
Aggressive
7 6 5 4 3 2 1
CS
IS -7
-6
-5
-4
-3
-2
-1
1
2
3
4
5
6
7
-1 -2 -3 -4 -5 -6
Competitive
-7
Defensive
ES Financial Stability (FS) Return on Investment Leverage Liquidity Working Capital Cash Flow
5 3 5 5 5
Environmental Stability (ES) Unemployment Technological Changes Price Elasticity of Demand Competitive Pressure Barriers to Entry
-4 -3 -2 -4 -4
Financial Stability (FS) Average
4.6
Environmental Stability (ES) Average
-3.4
Competitive Stability (CS) Market Share Product Quality Customer Loyalty Competition’s Capacity Utilization Technological Know-How
-1 -2 -2 -2 -2
Industry Stability (IS) Growth Potential Financial Stability Ease of Market Entry Resource Utilization Profit Potential
5 5 4 3 4
Competitive Stability (CS) Average
-1.8
Industry Stability (IS) Average
4.2
Copyright © 2011 Pearson Education Limited
Y-axis: FS + ES = 4.6 + (-3.4) = 1.2 X-axis: CS + IS = (-1.8) + (4.2) = 2.4
H.
Grand Strategy Matrix Rapid Market Growth Quadrant I
Quadrant II
Strong Competitive Position
Weak Competitive Position
Quadrant III
1. 2. 3. 4. 5. 6. 7.
Slow Market Growth
Market development Market penetration Product development Forward integration Backward integration Horizontal integration Related diversification
Copyright © 2011 Pearson Education Limited
Quadrant IV
I.
The Internal-External (IE) Matrix The IFE Total Weighted Score Strong 3.0 to 4.0 I
Average 2.0 to 2.99 II
Weak 1.0 to 1.99 III
IV
IV
VI
High 3.0 to 3.99
The EFE Total Weighted Score
Johnson & Johnson
Medium 2.0 to 2.99 VII
VIII
IX
Low 1.0 to 1.99
Copyright © 2011 Pearson Education Limited
J.
QSPM
Key Factors Opportunities 1. Smaller companies are coming up with new and innovative drugs. This creates an opportunity for larger drug companies to acquire or form a joint venture with smaller companies 2. Larger organizations have better purchasing power in buying raw material 3. The baby boomers are aging, therefore they have more need for health and medical services 4. More consumers are becoming health conscious by taking more vitamins and use better brand health related products 5. Due to economic downturn, many individuals may have more stress and depression and as such, may have a need for prescription drugs 6. Despite years of research, companies still spend money for developing new drugs for health issues related to cancer, heart problems, HIV and Alzheimer’s 7. Through the Internet, drug companies have found a more effective and less expensive way in advertising, educating, and promoting their products Threats 1. The cost of R&D has been increasing at an astounding rate, rising currently at a rate of eightfold per year 2. Due to economic downturn, there has been severe changes in the behavior and spending patterns of purchasers of healthcare products and services 3. Generic drug firms have filed Abbreviated New Drug Applications (ANDAs) seeking to
Weight
Acquire additional companies that are innovative and have pending patents on popular health related products AS TAS
Develop new health related products such as vitamins and dietary pills/drinks for health conscious consumers AS TAS
0.1
4
0.4
2
0.2
0.09
---
---
---
---
0.1
---
---
---
---
0.1
---
---
---
---
0.06
2
0.12
3
0.18
0.06
4
0.24
3
0.18
0.07
---
---
---
---
0.09
2
0.18
4
0.36
0.08
2
0.16
1
0.08
0.07
3
0.21
4
0.28
Copyright © 2011 Pearson Education Limited
market generic forms of most of the key pharmaceutical products, prior to expiration of the applicable patents covering those products 4. By 2012, many major patents, often referred to as Patent Cliffs, will expire, clearing the way for companies involved in the production of generics to begin manufacturing the most effective and high-grossing drugs on the market 5. Introducing a new drug into the market can take 10 to 15 years and require extensive amount of money to get it tested and receive FDA approval 6. Often, drugs could have side effects which create negative publicity and/or force the company to recall the drug or remove it from the shelves TOTAL Strengths 1. J&J offers a wide variety of products and services to hospitals, retailers, and families 2. The company does business in three segments: pharmaceutical, medical devices and consumer products 3. In July 2009, J&J purchased an 18.4 percent stake in Irish biotech company Elan Corp. in order to gain access to the US$3 billion market for Alzheimer's disease treatments. The effectiveness of the drug could help the company's sales by US$25 billion 4. In 2009, J&J acquired the small cancer drug-developer Cougar Biotechnology for about US$894 million in cash. Cougar has an excellent drug for late stage prostate cancer 5. At the end of 2008, J&J reported US$7.6 billion in research and developments expenditures, which was a slight decrease from 2007 6. Sales for both consumer health products and medical devices and diagnostics were up from 2007 to 2008 by 10.8 percent and 6.4 percent, respectively 7. The consumer products segment's operating profit increased 17.4 percent from 2007 to US$2,674 million in 2008 8. The pharmaceutical segment operating profit increased 16.3 percent from 2007, and operating profit increased to 31.0 percent to a total of $7,605 million in 2008
0.06
3
0.18
4
0.24
0.05
4
0.20
2
0.1
0.07
---
---
---
---
1.00
1.69
1.62
0.08
---
---
---
---
0.08
4
0.32
3
0.24
0.07
---
---
---
---
0.07
---
---
---
---
0.08
---
---
---
---
0.06
3
0.18
4
0.24
0.06
---
---
---
---
0.06
4
0.24
2
0.12
Copyright © 2011 Pearson Education Limited
9. Operating profit in medical devices segment increased 49.1 percent from 2007 to a total of US$7,223 million in 2008 Weaknesses 1. Sales for pharmaceutical segment was down from 2007 to 2008 by 1.2 percent 2. Patent on many of their popular and high volume drugs is about to expire 3. Increase in total liabilities by approximately US$4.8 billion from 2007 to 2008 4. In recent years, have not introduced any new innovative product unless by acquiring other companies 5. Per 2009 data, the company's quarterly sales dropped by 5.3 percent from the same period in prior year 6. The selling, general and administrating expenses to sales increased by 0.30 percent from 2007 to 2008 SUBTOTAL SUM TOTAL ATTRACTIVENESS SCORE
0.06
---
---
---
---
0.06
4
0.24
2
0.12
0.09
4
0.36
2
0.18
0.05
---
---
---
---
0.07
---
---
---
---
0.04
---
---
---
---
0.07
---
---
---
---
1.00
1.34 3.03
0.9 2.52
Recommendations Acquire companies that manufacture products not available currently through Johnson and Johnson product line and could fall under one of the company’s primary segment / product line.
Copyright © 2011 Pearson Education Limited
L.
EPS/EBIT Analysis
US$ Amount Needed: $1 billion Stock Price: US$64.74 Tax Rate: 23.5% Interest Rate: 5.46% # Shares Outstanding: 2.8 billion
Common Stock Financing
EBIT Interest EBT Taxes EAT # Shares EPS
Recession $28,000,000,00 0 0 28,000,000,000 6,580,000,000 21,420,000,000 2,815,446,401 7.61
EBIT Interest EBT Taxes EAT # Shares EPS
70 Percent Stock - 30 Percent Debt Recession Normal Boom $28,000,000,00 $30,000,000,00 $45,000,000,00 0 0 0 43,680,000 43,680,000 43,680,000 27,956,320,000 29,956,320,000 44,956,320,000 6,569,735,200 7,039,735,200 10,564,735,200 21,386,584,800 22,916,584,800 34,391,584,800 2,810,812,481 2,810,812,481 2,810,812,481 7.61 8.15 12.24
M.
Normal $30,000,000,00 0 0 30,000,000,000 7,050,000,000 22,950,000,000 2,815,446,401 8.15
Boom $45,000,000,00 0 0 45,000,000,000 10,575,000,000 34,425,000,000 2,815,446,401 12.23
Debt Financing Recession $28,000,000,000 54,600,000 27,945,400,000 6,567,169,000 21,378,231,000 2,800,000,000 7.64
Normal $30,000,000,00 0 54,600,000 29,945,400,000 7,037,169,000 22,908,231,000 2,800,000,000 8.18
Boom $45,000,000,000 54,600,000 44,945,400,000 10,562,169,000 34,383,231,000 2,800,000,000 12.28
70 Percent Debt - 30 Percent Stock Recession Normal Boom $30,000,000,00 $28,000,000,000 0 $45,000,000,000 10,920,000 10,920,000 10,920,000 27,989,080,000 29,989,080,000 44,989,080,000 6,577,433,800 7,047,433,800 10,572,433,800 21,411,646,200 22,941,646,200 34,416,646,200 2,804,633,920 2,804,633,920 2,804,633,920 7.63 8.18 12.27
Epilogue
The U.S. Congress has been discussing plans to pass a national healthcare program which could impact the drug companies and how they do business in the United States. If the healthcare reform is passed, more individuals could afford to have health insurance and accordingly use products or services prescribed by their physician. On the other hand, there may be some requirements in regards to lowering prices on products or services by the drug manufacturers. In recent months, Johnson & Johnson has announced several victories such as unveiling “Cytomimic Technology” which is related to how the body’s electrical field affects skin regression; reaching an agreement between Cordis Corporation (owned by Johnson & Johnson) with Boston Scientific resolving two litigations; receiving an approval from the U.S. Food and Drug Administration for labeling update for Prezista tablets; and an increase in sales of 9.0 percent in the fourth quarter of 2009 compared to the same period in 2008.
Copyright © 2011 Pearson Education Limited
